Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab

  title={Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab},
  author={M. Clerico and S. D. De Mercanti and C. Artusi and L. Durelli and R. Naismith},
  journal={Multiple Sclerosis Journal},
  pages={874 - 876}
Alemtuzumab is a humanized monoclonal antibody targeting the surface molecule CD52, resulting in a rapid depletion of innate and adaptive immune cells. Infection rates in multiple sclerosis (MS) treatment trials were higher in alemtuzumab than in interferon beta–treated patients. We report two MS patients who developed cytomegalovirus disease within 1 month after the first 5-day cycle of alemtuzumab. Upon identification and appropriate treatment of the infection, each recovered completely… Expand
34 Citations
Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis.
  • 8
Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis
  • 29
Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
  • 31
  • PDF
Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
  • 10
  • PDF


Alemtuzumab for Multiple Sclerosis
  • 50
  • PDF
The evolving role of Alemtuzumab in management of patients with CLL
  • 31
  • PDF
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
  • K. Rai, C. Freter, +6 authors L. Brettman
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
  • 326
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
  • 422
Herpes infection risk reduced with acyclovir prophylaxis after alemtuzumab. In: Presented as poster at the annual meeting of the consortium for multiple sclerosis
  • centers, Orlando, FL,
  • 2013